Povlsen Johan V, Ivarsen Per
Department of Renal Medicine C, Aarhus University Hospital, Skejby Hospital, Aarhus, Denmark.
Perit Dial Int. 2005 Feb;25 Suppl 3:S60-3.
To describe basic demographics and clinical outcomes among elderly end-stage renal disease (ESRD) patients physically dependent on a caregiver and maintained on an assisted automated peritoneal dialysis (AAPD) program.
Retrospective single-center study based on patient records and data files.
University Hospital.
64 physically dependent AAPD patients followed for 1.012 treatment months. Assistance and care was delivered by 52 briefly trained teams of visiting nurses or nursing home staff.
Crude 1-year survival was 58% and 2-year survival was 48%. Crude 1- and 2-year survivals, excluding deaths within 90 days, were 66% and 54% respectively. We found no significant effect on survival by main causes of ESRD, gender, age, late referral, need for acute start, social isolation, physical dependency on help at inclusion, or residence in a nursing home. 10% of patient-days on AAPD were spent in hospital. 13 (20%) of the patients were converted permanently to hemodialysis due to PD technique failure. The incidence of peritonitis was 1 in every 25.3 treatment-months.
AAPD may be a feasible and safe option for renal replacement therapy for frail, elderly, and physically dependent patients with ESRD. Despite the special patient selection for this AAPD program, we achieved results of international standards for patient survival, PD technique survival, and incidence of acute peritonitis. These results do notjustify withholding dialysis from this group of patients.
描述身体依赖照护者并维持辅助自动化腹膜透析(AAPD)方案的老年终末期肾病(ESRD)患者的基本人口统计学特征和临床结局。
基于患者记录和数据文件的回顾性单中心研究。
大学医院。
64例身体依赖他人的AAPD患者,随访1012个治疗月。援助和护理由52个经过短期培训的访视护士或养老院工作人员团队提供。
1年粗生存率为58%,2年粗生存率为48%。排除90天内死亡情况后的1年和2年粗生存率分别为66%和54%。我们发现,ESRD的主要病因、性别、年龄、延迟转诊、急性起始需求、社会隔离、纳入时身体依赖他人帮助或居住在养老院对生存率均无显著影响。AAPD患者住院天数占总天数的10%。13例(20%)患者因腹膜透析技术失败而永久性转为血液透析。腹膜炎发生率为每25.3个治疗月1例。
对于体弱、老年且身体依赖他人的ESRD患者,AAPD可能是一种可行且安全的肾脏替代治疗选择。尽管该AAPD方案有特殊的患者选择标准,但我们在患者生存率、腹膜透析技术生存率和急性腹膜炎发生率方面达到了国际标准。这些结果表明不应拒绝为这类患者进行透析治疗。